Revvity Schedules Q1 2026 Earnings Call

The biotech company will report results and host a conference call on May 5, 2026.

Apr. 10, 2026 at 4:41pm

Got story updates? Submit your updates here. ›

A minimalist studio still life featuring a stack of financial reports, a calculator, and a pen on a clean, monochromatic background, conceptually representing corporate finance and earnings reports.Revvity's upcoming earnings call will provide investors with the latest financial updates on the pharmaceutical company's performance.Waltham Today

Revvity, Inc., a publicly traded biotech firm based in Waltham, Massachusetts, announced that it will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The company will also host a conference call that same day at 7:30 a.m. ET to discuss the quarterly results.

Why it matters

As a major biotech player, Revvity's quarterly earnings reports and conference calls provide important updates on the company's financial performance and product pipeline, which can impact investor sentiment and the stock price.

The details

Revvity, which trades on the New York Stock Exchange under the ticker symbol RVTY, will report its Q1 2026 results prior to the market open on May 5th. The company's president and CEO, Prahlad Singh, will host the earnings call at 7:30 a.m. Eastern Time that same day to discuss the quarterly numbers and provide commentary on Revvity's business.

  • Revvity will release Q1 2026 financial results on Tuesday, May 5, 2026.
  • Revvity will host an earnings conference call at 7:30 a.m. ET on Tuesday, May 5, 2026.

The players

Revvity, Inc.

A publicly traded biotech company based in Waltham, Massachusetts that develops and manufactures pharmaceutical and diagnostic products.

Prahlad Singh

The president and chief executive officer of Revvity, Inc.

Got photos? Submit your photos here. ›

The takeaway

Revvity's upcoming earnings report and conference call will provide investors with important updates on the company's financial performance and strategic direction as it navigates the competitive biotech landscape.